Advertisement
Screener

RHYTHM PHARMACEUTICALS, INC. (RYTM) Capital Expenditures

2.8 / 5 stars · 68/120 Roast Me

RHYTHM PHARMACEUTICALS, INC. Capital Expenditures

RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Capital Expenditures of $953.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-02-26

  • RHYTHM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was -$1.00K.
  • RHYTHM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $1.00K, a 98.95% decline year-over-year.
  • RHYTHM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
  • RHYTHM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2023-03-31 was $47.00K, a 62.99% decline year-over-year.
  • RHYTHM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $953.00K.
  • RHYTHM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
  • RHYTHM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $47.00K, a 83.27% decline from fiscal 2022.
  • RHYTHM PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $281.00K, a 35.25% decline from fiscal 2021.
Period endPayments to Acquire Property, Plant, and Equipment 3 monthPayments to Acquire Property, Plant, and Equipment 6 monthPayments to Acquire Property, Plant, and Equipment 9 monthPayments to Acquire Property, Plant, and Equipment 12 month
2025-12-31$953.00K
10-K · filed 2026-02-26
2024-12-31$0.00
10-K · filed 2026-02-26
2023-12-31-$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$0.00
derived: sum of 2 quarters · filed 2026-02-26
$0.00
derived: sum of 3 quarters · filed 2026-02-26
$47.00K
10-K · filed 2026-02-26
2023-09-30$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
$1.00K
derived: sum of 2 quarters · filed 2024-11-06
$48.00K
10-Q · filed 2024-11-06
$47.00K
derived: sum of 4 quarters · filed 2025-02-28
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$47.00K
10-Q · filed 2024-08-06
$46.00K
derived: sum of 3 quarters · filed 2025-02-28
$141.00K
derived: sum of 4 quarters · filed 2025-02-28
2023-03-31$47.00K
10-Q · filed 2024-05-07
$46.00K
derived: sum of 2 quarters · filed 2025-02-28
$141.00K
derived: sum of 3 quarters · filed 2025-02-28
$201.00K
derived: sum of 4 quarters · filed 2025-02-28
2022-12-31-$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28
$94.00K
derived: sum of 2 quarters · filed 2025-02-28
$154.00K
derived: sum of 3 quarters · filed 2025-02-28
$281.00K
10-K · filed 2025-02-28
2022-09-30$95.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$155.00K
derived: sum of 2 quarters · filed 2023-11-08
$282.00K
10-Q · filed 2023-11-08
$350.00K
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$60.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01
$187.00K
10-Q · filed 2023-08-01
$255.00K
derived: sum of 3 quarters · filed 2024-02-29
$361.00K
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31$127.00K
10-Q · filed 2023-05-02
$195.00K
derived: sum of 2 quarters · filed 2024-02-29
$301.00K
derived: sum of 3 quarters · filed 2024-02-29
$549.00K
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$68.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$174.00K
derived: sum of 2 quarters · filed 2024-02-29
$422.00K
derived: sum of 3 quarters · filed 2024-02-29
$434.00K
10-K · filed 2024-02-29
2021-09-30$106.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$354.00K
derived: sum of 2 quarters · filed 2022-11-08
$366.00K
10-Q · filed 2022-11-08
$450.00K
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$248.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$260.00K
10-Q · filed 2022-08-03
$344.00K
derived: sum of 3 quarters · filed 2023-03-01
2021-03-31$12.00K
10-Q · filed 2022-05-03
$96.00K
derived: sum of 2 quarters · filed 2023-03-01
2020-12-31$84.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$214.00K
10-K · filed 2023-03-01
2020-09-30$130.00K
10-Q · filed 2021-11-02
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$259.00K
derived: sum of 2 quarters · filed 2021-03-01
$2.57M
derived: sum of 3 quarters · filed 2021-03-01
$3.38M
10-K · filed 2021-03-01
2019-09-30$259.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02
$2.57M
derived: sum of 2 quarters · filed 2020-11-02
$3.38M
10-Q · filed 2020-11-02
$3.78M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30$2.31M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03
$3.13M
10-Q · filed 2020-08-03
$3.52M
derived: sum of 3 quarters · filed 2021-03-01
$3.84M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31$811.00K
10-Q · filed 2020-05-04
$1.21M
derived: sum of 2 quarters · filed 2021-03-01
$1.52M
derived: sum of 3 quarters · filed 2021-03-01
2018-12-31$395.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$712.00K
derived: sum of 2 quarters · filed 2021-03-01
$722.00K
10-K · filed 2021-03-01
2018-09-30$317.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01
$327.00K
10-Q · filed 2019-11-01
2018-06-30$10.00K
10-Q · filed 2019-07-29
2017-12-31$55.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
$133.00K
10-K · filed 2020-03-02
2017-09-30$78.00K
10-Q · filed 2018-11-09
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08
$1.06M
10-K · filed 2019-03-08
2016-09-30$1.06M
10-Q · filed 2017-11-14
2015-12-31$17.00K
8-K · filed 2018-11-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alkermes plc. (ALKS)$6.844B132.74
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60